Phil B.FontanarosaMD, Deputy EditorIndividualAuthorMargaret A.WinkerMD, Deputy EditorIndividualAuthorStephen J.LurieMD, PhD, Fishbein FellowIndividualAuthor
Copyright 2000 American Medical Association. All Rights Reserved.
Applicable FARS/DFARS Restrictions Apply to Government Use.2000
In Reply: The ER status of breast cancer was
determined based on clinical reports from the numerous sites that participated
in this international study; it was not feasible to mandate a single method.
Variability in the assessment of ER status might have led our study to underestimate
the differential effect of raloxifene on ER-positive and ER-negative cancer;
however, we found that these effects of raloxifene on risk of ER-positive
and ER-negative cancer were extremely different.
Cummings SR, Grady D, Black D, Eckert S, Krueger KA, Nickélsen T, Glusman JE, Powles TJ, Cauley JA, Norton L, Bjarnason NH, Morrow M, Jordan VC, Lippman ME, Costa A. Estrogen-Receptor Status in Breast Cancer—Reply. JAMA. 2000;283(3):338-339. doi:10-1001/pubs.JAMA-ISSN-0098-7484-283-3-jac90010